It’s not often you get excited talking about company mergers, but a deal announced today is something worth getting excited about, particularly if you have type 1 diabetes (T1D). Today Vertex announced it was buying ViaCyte for $320 million in cash. Why is that important? Because both companies are working on developing stem cell therapies … Continue reading A big deal for type 1 diabetes
THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST Taking even the most promising therapy and moving it out of the lab and into people is an incredibly complex process and usually requires a great team. Now, two great teams have paired up to do just that with a therapy for type 1 diabetes (T1D). … Continue reading Type 1 diabetes therapy gets go-ahead for clinical trial
LISTEN TO THIS BLOG AS AN AUDIOCAST ON SPOTIFY Type 1 diabetes (t1d) affects every aspect of a person’s life, from what they eat and when they eat, to when they exercise and how they feel physically and emotionally. Because the peak age for being diagnosed with t1d is around 13 or 14 years of … Continue reading Creating a better way to treat type 1 diabetes
THIS BLOG IS ALSO AVAILABLE AS AN AUDIOCAST As someone with a family history of type 1 diabetes (T1D) I know how devastating the condition can be. I also know how challenging it can be to keep it under control and the consequences of failing to do that. Not maintaining healthy blood sugar levels can … Continue reading Getting under the skin of people with type 1 diabetes – but in a good way
We were saddened to learn today of the death of Susan Solomon, the CEO and co-founder of the New York Stem Cell Foundation (NYSCF), a non-profit organization that supports stem cell research around the world. As CEO, Ms. Solomon raised over $400M for stem cell research, helping to catalyze the field and transform the future … Continue reading Mourning the death of Susan Solomon
THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST One of the huge advantages of a stem cell agency like CIRM (not that there is anything out there quite like us, but anyway) is our ability to support projects as they progress from a great idea to a therapy actually being tested in people. Exhibit … Continue reading Producing insulin for people who can’t
THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST There’s some good news for a company and a therapeutic approach that CIRM has been supporting for many years. In September 2018, CRISPR Theraputics and ViaCyte entered a partnership to discover, develop and market gene-edited stem cell-derived therapies to treat type 1 diabetes (T1D). Today, they may stand … Continue reading First Patient Dosed in Phase 1 Clinical Trial for T1D
By Stephen Lin, PhD., CIRM Senior Science Officer Type 1 diabetes affects millions of people. It is a disease where beta islet cells in the pancreas are targeted by the body’s own immune system, destroying the ability to produce insulin. Without insulin, the body cannot break down sugars from the bloodstream that produce energy for … Continue reading Scientists develop immune evading pancreas organoids to treat type 1 diabetes
THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST This year was a momentous one for the California Institute for Regenerative Medicine (CIRM). We celebrated the passage of Proposition 14, and as a result, introduced our new strategic plan and added a group of talented individuals to our team. We shared our most exciting updates and newsworthy stories—topics ranging from stem cell research to diversity … Continue reading The Most Read Stem Cellar Blog Posts of 2021
As someone who is not always as diligent as he would like to be about sending birthday cards on time, I’m used to sending belated greetings to people. So, I have no shame in sending belated greetings to four CIRM grantees who were inducted into the National Academy of Medicine in 2020. I say four, … Continue reading National Academy of Medicine honors CIRM Grantees
The Stem Cellar 